Medicxi's returns keep flowing as Celgene's Inrebic approval delivers milestone

Friday's approval of myelofibrosis drug Inrebic fedratinib added to the windfall European venture firm Medicxi has realized from its relatively modest October 2017 investment in Impact Biomedicines Inc., likely returning more total cash than Medicxi raised for its entire first fund.

With FDA's approval of Inrebic from Celgene Corp.

Read the full 480 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE